Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't post much but wanted to chime in with the recent developments. I once was a hater of ONCS I mean I couldn't stand the company but about a year ago I spoke with Punit in San Diego and it's then that I understood a lot of what ONCS was doing and a lot of how tiny biotech's work. Most of the time the market ignores these companies and it takes phenomenal results plus perfect timing to really truly prosper. Punit told me back then that the true value of ONCS wouldn't be recognized until a deal was struck. Well I think with the addition of Dan (yes has a past but it's all speculation as to what really happened) this deal is imminent. Reason the more time goes by the more expensive OncoSec gets because of the risk factor is diminished. Merck knows I believe what OncoSec can do and with Punit running the show his inexperience in deal making was hindering a possible deal. Licensing is where the money truly is for OncoSec but Merck I believe will do everything they can to not allow this to happen. Dan is there for negotiation purposes period!! Again this is my take and this is what I believe do your own DD and draw your own conclusions but I think the story is becoming more clear.
I didn't miss anything. Your point is further dilution is needed to bring drug to market. The board's view is no further dilution is needed because of recent comments by our CEO Dr. Glickman. Now to sway the boards view on this topic you post an article where H.C. Wainwright downgrades there price target due to further dilution. Except you failed to mention that in that specific article H.C. says this downgrade in price target is without taking into the consideration that Europe and Japan could be huge future revenue streams. With those revenue streams dilution would not be needed. Now Glickman who is privy to more information than anyone including H.C. and yourself stated that no further dilution would be needed. Why? Hello? Cause he knows he is sitting on a golden egg.
You fail to mention that H.C. Wainwright was not taking into consideration any partnerships for Europe or Japan. Also what should be noted is today Morgan Stanley made of purchase of 446k shares. New institutional investors are buying daily because they realize the huge potential this company has and how they will once approved be the (SOC) for Lupus Nephritis.
I believe both of you are correct! Speaking of moving the needle today's action to me was a little surprising. Does anyone have any thoughts on it? My take is pure manipulation but what surprised me was the spike at the open to then quickly have the bottom fall out of it. This company is so undervalued and de-risked then any other biotech I have come across. Good luck longs we will prevail and remember trust your own DD!
This one was wound so tight and rubbing up against the 50 day MA on the daily. I believe just a bounce off that support. But who knows this one should be trading in the double digits so....?
I'm a regular to this board never posting but always reading posts and taking all of them in. My question for the (ARIA) investors who profited from the BO were you certain that a buyout was the end result or shocked? Another question for more educated investors who know the process of approval why would Voclosporin not be eligible for early approval? My personal opinion on a buyout of AUPH I believe that it will come much sooner than people think. I also believe that we can agree the longer big pharma waits to make a deal the more they will have to pay because the asset (voclosporin) becomes further de-risked. Thanks for all the informative posts and look forward to reading more of them.
Any comments from posters on upcoming data release? Data expected to show efficacy?
Yea stock is way to cheap. However there are alot of bargains in mind out there in the bio space. I do like a run-up here soon to data so expecting a nice return shortly. I sent email yesterday to management i will pass along message when i get response.
Thanks Ash yea found this info yesterday.
Ash sorry to bother but was hoping for a little help in regards to presentation where its mentioned possible partnership? If you can please elaborate? Thanks!
Looks ugly here? All small caps have been sh*t the past month and throw in that its a biotech and you get this drop. Fundamentals solid with Analysis coverage all valuing with minimum 300% returns from here. So this wave of negative sentiment will pass and most likely shortly after the election is over. To say this is headed back to 2 is most likely a call from someone who has an agenda? Continue to play with fire and you will be burned my friend.
Not worried a bit they will burn if they continue to play with fire!
Yea I'm gonna continue to average down but for now I'm gonna wait and see where this thing bottoms out. It's been in a free fall with all this uncertainty in the sector. Any guesses to where she will bottom? I'm thinking the 50 day (MA). But like I said with all this noise and that is all it is noise, the stock could hit 3 and bottom.
Yes it's a "standard phase 1- single-ascending and multiple-ascending dose in healthy volunteers. The oral SCY-078 was more historically advanced than the IV formulation. This phase 1 trial serves as a required validation of our IV formulation so we can move forward in all subsequent studies with both IV + oral SCY-078." This is the exact message I received from the CFO. So with that said I expect nothing but success in this trial and furthermore I see them partnering soon for Europe.
Listen to there latest conference. Ladenburg Healthcare conference. IV data from phase I trial.
yea picked up only 700 shares at 4.00 and 3.94. Loaded n ready for the run into November data release and beyond. Truly love the potential here.
yes sir loading the boat here.
Can anyone tell me please if Monday's poster presentations are old news or new data not seen? I'm not sure of conference policy?
Ok I was posting about SCYX n your posting about some other stock on the SCYX platform? Sorry I was thinking of SCYX
That's funny enlighten me please as too what drug in there pipeline is in phase 3?
Pat Summitt one of the greatest woman's basketball coaches of all time passes today. She changed how we view woman's sports not only basketball. She dies from Alzheimer's so let's hope AVXL can make at least a difference with this strategic disease.
One more thing I would like to add. During the first quarter conference call Jeff mentions that who ever partners with SYN 010 believes will not only partner for the current indication but will seek further label expansion into other indications. So with that being said I think SYN 010 will be partnered and SYN 004 will be brought to market by Synthetic. SYN 004 phase III is scheduled to begin in 2017. In other words I believe financing is further down the line.
My personal opinion on this subject is I believe a financing deal will take place but after the phase IIb interim results. I don't think it would be a smart move to raise funds now when pps is in a downtrend. Raise after great results. I always refer back to Kerxy when they announced positive phase III data n immediately did a financing deal which did not influence the stock negatively. Raise into positive news. Of. Course this is my opinion and also what I'm hoping for.
American Society of biologics is posted as event on there website? R we presenting? If so what? Phase IIb blinded data?
This decline has nothing to CPRX but rather the whole sector in general that has been under complete disarray.
Never mind I was just informed I'm a retard. Incorrect info disregard
Interesting conference end of the month into the beginning of April. Conference takes place in Vienna and there are some interesting names on tap to speak. Our own Dr. Fisher is one of them.
Might we see part B data then? The suspense is killing me.
Question fellow shareholders I need some clarification on this presentation this weekend. Will Anavex be presenting cause I cannot find them in program. Thanks in advance.
OCT is not fine and conversations with Dr. Wilson leads me to believe uplifting will be sooner rather than later. I predict this is done in first half of this year.
With all due respect Capt. all stocks on the market are "POS", none are performing well and if the science succeeds as you say this will become a bright spot in a sea of red for 2016.
Really CTAD isn't a scientific conference? Next
Ok I'm done. I was simply stating my opinion based off conversations I have had with Dr. Missling. I don't need to prove myself to anyone on this board about my agenda or if I have actually spoken to Dr. Missling. I don't care. There are other posters here that know of my sincere opinion on matters of AVXL. Good luck guys!
I suggest all here set-up a call with Missling.
Did I say that
For all expecting updates at those specified intervals will be extremely disappointed.
Nothing was promised.
I have spoken to Dr. Missling on several occasions and I believe that we are farther off from a data release then one might think. Of course this is my opinion but I take Missling for his word. He will present data at a scientific conference and nothing short of that.
I spoke with Glynn almost two weeks ago and he stressed to me that in the big pharma world the simplest of tasks sometimes takes a ridiculous amount of time. The collaboration has been signed by both Tapimmune and the prestigious institute. The remaining signature rests with big pharma. I'm certain it will be announced this month along with other developments
Absolutely I personally had written Trimesta off. I will be buying cheap today and stealing shares. I don't suspect it to be hammered, however I could be wrong.